Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
5-Amino-1MQ vs Survodutide
An educational, source-based comparison of 5-Amino-1MQ and Survodutide — how each peptide works, what it's researched for, and what to know before going deeper.
Not a peptide but commonly grouped in peptide research. A selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Inhibition increases SAM and NAD+ availability, increasing adipocyte energy expenditure in animal models.
- Diet-induced obesity (rodent)
- White adipose tissue energy expenditure
- Age-related muscle function
- • Investigational; no human clinical trials yet.
- • Not FDA-approved.
A dual agonist of the GLP-1 and glucagon receptors. The glucagon arm adds an energy-expenditure component on top of GLP-1's appetite and glycemic effects.
- Chronic weight management
- MASH / fatty liver disease
- Type 2 diabetes
- • Investigational; not yet FDA-approved.
- • GI side effects are dose-limiting.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibition reduces adiposity in obese mice | Nature Medicine | 2015 | Demonstrated weight loss and improved metabolic profile via NNMT inhibition. |
| Survodutide | Survodutide for obesity (Phase 2) | The Lancet Diabetes & Endocrinology | 2024 | Up to ~19% mean weight loss at 46 weeks. |
Side-effect & safety grid
- Investigational; no human clinical trials yet.
- Not FDA-approved.
- Investigational; not yet FDA-approved.
- GI side effects are dose-limiting.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
5-Amino-1MQ vs Survodutide — Key differences
- Class: 5-Amino-1MQ is classified as Metabolic · Small Molecule, while Survodutide is Metabolic · Incretin.
- Primary research focus: 5-Amino-1MQ — diet-induced obesity (rodent); Survodutide — chronic weight management.
- Tag: Metabolic vs Weight loss.